what's in glp 1 GLP-1 Medications Infographic Structural and functional diversity among

Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation

Side effects are typically mild injection-site reactions, flushing, increased heart rate, nausea, headache

Common side effects are typically mild and transient: Pain, redness, or swelling at the injection site (most frequent) Mild diarrhoea or gastrointestinal upset Headache or dizziness shortly after administration Itching or mild skin reactions Temporary pink/red discolouration of urine These effects usually resolve within 2448 hours without intervention

After consideration of public comments, we are finalizing our proposal without modification to make the following two-stage methodologic updates to the Overall Hospital Quality Star Rating to emphasize the Safety of Care measure group (applicable to hospitals with at least three measures in the Safety of Care Measure Group): Stage 1: Implement a 4-star cap for hospitals in the lowest quartile of the Safety of Care measure group performance beginning in 2026 followed by Stage 2: Implement a blanket 1-star reduction for hospitals in the lowest quartile of Safety of Care measure group performance for the 2027 Overall Hospital Quality Star Ratings and later years